Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 5, 2010, Pages 436-451

  Yamashita, Shizuya ^a   Tsubakio Yamamoto, Kazumi ^a   Ohama, Tohru ^a   Nakagawa Toyama, Yumiko ^b   Nishida, Makoto ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Apolipoprotein a i; Atp binding cassette transporter a1; Cholesteryl ester transfer protein; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LIPASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PITAVASTATIN; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SCAVENGER RECEPTOR BI; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ACHILLES TENDON XANTHOMA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CALCIUM TRANSPORT; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; ENZYME DEGRADATION; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; XANTHOMA;

EID: 77953355430     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5405     Document Type: Review

References (156)

1. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988; 4 Suppl A: 5A-10A
2. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H: The inverse relationship etween serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow up study in the Japanese general population. Atherosclerosis, 2006; 184: 143-150
3. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 2007; 370: 1829-1839
4. Brewer HB Jr: High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascu-lar disease. Arterioscler Thromb Vasc Biol, 2004; 24: 387-391
5. Singh IM, Shishehbor MH, Ansell BJ: High-density lipoprotein as a therapeutic target: a systematic review. JAMA, 2007; 298: 786-798
6. Assmann G, Gotto AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation, 2004; 109: 8-14
7. Ansell BJ, Fonarow GC, Fogelman AM: High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep, 2006; 8: 405-411
8. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310
9. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Saito Y, Sasaki J, Shimamoto K, Itakura H: Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis, 2007; 191: 440-446
10. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro, T: Effect of pravastatin on malondialdehyde-modi-fied low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol, 2005; 96: 1089-1094
11. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J, 2009; 73: 2110-2117
12. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J, 2002; 66: 1087-1095
13. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1096-1100
14. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVE study). Am J Cardiol, 1998; 81: 582-587
15. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol, 2003; 92: 152-160
16. Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, Mabuti H, Tsushima M, Sasaki J, Ogawa N, Goto Y: Clinical efficacy of NK-104(Pitavastatin), a new synthetic HMG-CoA Reductase inhibitor, in the dog finding, double blind, three-group comparative study. J Clin Ther Med, 2001; 17: 829-855
17. Branchi A, Fiorenza AM, Torri A, Muzio F, Berra C, Colombo E, Dalla Valle E, Rovellini A, Sommariva D: Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. Clin Ther, 2001; 23: 851-857
18. Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca P, Ramsey KE, Hustad CM, Palmisano J: Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J, 2003; 146: 862-869
19. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ: The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardio-vascular diseases. Curr Mol Med, 2006; 6: 571-587
20. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ: Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. J Lipid Res, 2009;: [Epub ahead of print]
21. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J, 2002; 144: 1036-1043
22. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J, 2002; 144: 1044-1051
23. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S: A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101
24. Teramoto T, Saito Y, Yamada N, Itakura H, Hata Y, Nakaya N, Mabuchi H, Sasaki J, Ogawa N, Goto Y: Clinical safety and efficacy of NK-104 (Pitavastatin) in the long term treatment of hyperlipidemia: results of a multicenter long-term study. J Clin Ther Med, 2001; 17: 885-914
25. Teramoto T, Shimano H, Yokote K, Urashima M: Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb, 2009; 16: 654-661
26. McTaggart F, Jones P: Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther, 2008; 22: 321-338
27. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest, 2001; 107: 1423-1432
28. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipo-protein A-I production in HepG2 cell. Biochem Biophys Res Commun, 2004; 324: 835-839
29. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther, 2004; 311: 420-425
30. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T: Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem, 2007; 282: 21090-21099
31. Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta, 2000; 1529: 245-256
32. Liang K, Kim CH, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol, 2005; 288: F539-F544
33. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K: Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. Eur J Clin Invest, 2006; 36: 224-230
34. Meijer GW, Groener JE, Beynen AC, Van Tol A: Lowering of serum cholesteryl ester transfer protein--but not lecithin:cholesterol acyltransferase--activity levels by hypocholesterolemic drugs in the rabbit. Cardiovasc Drugs Ther, 1998; 12: 13-18
35. Walker RJ, Sutherland WH, Walker HL, MacMahon S, Robson RA: Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrol Dial Transplant, 1997; 12: 87-92
36. Fusegawa Y, Tada H, Oguma T, Shiina Y, Moriguchi EH, Tanabe T, Tamachi H, Tomoda H, Goto Y: Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia. Tokai J Exp Clin Med, 1993; 18: 81-86
37. Lijnen P, Celis H, Desager JP, Fagard R: Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. J Hum Hypertens, 1995; 9: 557-564
38. Desager JP, Horsmans Y, Harvengt C: Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus lowdose colestipol. J Clin Pharmacol, 1991; 31: 537-542
39. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJ: Effect of treatment with a hydroxy-methylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes, 1995; 44: 460-465
40. Napoli C, Leccese M, Palumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, Di Loreto M, De Matteis, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento FP: Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis, 1998; 9: 257-264
41. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW: Regulation of acrophage cholesterol efflux through hydroxymethylgl-utaryl-CoA reductase inhibition: a role for RhoA in ABCA1 ediated cholesterol efflux. J Biol Chem, 2005; 280: 22212-22221
42. Sone H, Shimano H, Shu M, Nakakuki M, Takahashi A, Sakai M, Sakamoto Y, Yokoo T, Matsuzaka K, Okazaki H, Nakagawa Y, Iida KT, Suzuki H, Toyoshima H, Horiuchi S, Yamada N: Statins downregulate ATP-bind-ing-cassette transporter A1 gene expression in macro-phages. Biochem Biophys Res Commun, 2004; 316: 790-794
43. Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR: Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J Lipid Res, 2006; 47: 2248-2258
44. Wong J, Quinn CM, Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol, 2004; 24: 2365-2371
45. Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ: The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis, 2008; 196: 180-189
46. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR: Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem, 1997; 272: 20982-20985
47. Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J: Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta, 2006; 365: 119-124
48. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM Jr, Hajjar, DP: Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation, 2004; 110: 3472-3479
49. Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, Kurose H, Murakami M, Okajima F: Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol, 2008; 181: 7332-7340
50. Lopez D, McLean MP: Sterol regulatory element-bind-ing protein-1a binds to cis elements in the promoter of the rat high density lipoprotein receptor SR-BI gene. Endocrinology, 1999; 140: 5669-5681
51. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP: Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia, 2005; 48: 1105-1113
52. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM: Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care, 2003; 26: 1216-1223
53. Kawano M, Nagasaka S, Yagyu H, Ishibashi S: Pitavas-tatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholester-olemic patients. J Atheroscler Thromb, 2008; 15: 41-46
54. Kappelle PJ, Zwang L, Huisman, MV, Banga, JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP: Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opin Ther Targets, 2009; 13: 743-751
55. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, Nestel P: Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008; 197: 732-739
56. Masson D, Staels B, Gautier T, Desrumaux C, Athias A, Le Guern N, Schneider M, Zak Z, Dumont L, Deckert V, Tall A, Jiang XC, Lagrost L: Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res, 2004; 45: 543-550
57. McPherson R: Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol, 1999; 6: 85-90
58. Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthézène F, Chapman MJ: Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 1995; 15: 1359-1368
59. de Haan W, van der Hoogt C C, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, Havekes LM, Rensen PC: Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Athero-sclerosis, 2008; 197: 57-63
60. Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S: Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA, 1978; 75: 4519-4523
61. Merkel M, Eckel RH, Goldberg IJ: Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res, 2002; 43: 1997-2006
62. Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med, 2002; 80: 753-769
63. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, Otsuka M, Ito Y, Shirai K: Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb, 2004; 11: 341-347
64. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA: Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis, 2004; 175: 325-331
65. Isley WL, Miles JM, Patterson BW, Harris WS: The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mel-litus. J Lipid Res, 2006; 47: 193-200
66. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K: Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12: 163-168
67. Applebaum-Bowden D, Haffner SM, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Hazzard WR: Postheparin plasma triglyceride lipases. Relationships with very low density lipoprotein triglyceride and high density lipoprotein2 cholesterol. Arteriosclerosis, 1985; 5: 273-282
68. Kuusi T, Saarinen P, Nikkilä EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis, 1980; 36: 589-593
69. Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H: Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care, 2003; 26: 427-432
70. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ: A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet, 1999; 21: 424-428
71. Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T: Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem, 1999; 274: 14170-14175
72. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ: Characterization of the lipolytic activity of endothelial lipase. J Lipid Res, 2002; 43: 921-929
73. Kojima Y, Ishida T, Sun L, Yasuda T, Toh R, Rikitake Y, Fukuda A, Kume N, Koshiyama H, Taniguchi A, Hirata KI: Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo. Cardiovasc Res, 2010; Epub
74. Bey L, Maigret P, Laouenan H, Hamilton MT: Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglycer-ide-lowering drug. Pharmacology, 2002; 66: 51-56
75. Yasuda T, Hirata K, Ishida T, Kojima Y, Tanaka H, Okada T, Quertermous T, Yokoyama M: Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages. J Atheroscler Thromb, 2007; 14: 192-201
76. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: Adiponectin as a biomarker of the metabolic syndrome. Circ J, 2004; 68: 975-981
77. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii K, Ishigami M, Nishida M, Hirano K, Kihara S, Hori M, Shimomura I, Yamashita S: Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun, 2007; 358: 1091-1095
78. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Ohama T, Ishigami M, Nishida M, Hirano K, Kihara S, Hori M, Shimomura I, Yamashita S: Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett, 2007; 581: 5029-5033
79. Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, Nakatani K, Nakaoka H, Kawase R, Yuasa-Kawase M, Masuda D, Ohama T, Maeda N, Nakagawa-Toyama Y, Ishigami M, Nishida M, Kihara S, Shimomura I, Yamashita S: Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun, 2008; 375: 390-394
80. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, Fukuhara A, Shimomura I: Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol, 2008; 28: 871-877
81. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, Sakamoto T, Horibata Y, Watanabe K, Koga H, Sugamura K, Otsuka F, Shimomura I, Ogawa H: Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis, 2007; 194: e43-e51
82. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, Koh Y, Shin EK: Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care, 2008; 31: 776-782
83. Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Kitta Y, Kobayashi T, Mende A, Kugiyama K: Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis, 2007; 193: 449-451
84. Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesauro M, Lauro D: Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis, 2009; Epub:
85. Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Nanba M, Shouda Y, Iwasaka T: Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb, 2008; 36: 1-8
86. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122
87. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med, 2007; 356: 1304-1316
88. Kontush A, Guérin M, Chapman MJ: Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med, 2008; 5: 329-336
89. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM: Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation, 2009; 120: 2414-2420
90. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y: Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol, 1997; 17: 1053-1059
91. Yamashita S, Sakai N, Hirano K, Arai T, Ishigami M, Maruyama T, Matsuzawa Y: Molecular genetics of plasma cholesteryl ester transfer protein. Curr Opin Lipidol, 1997; 8: 101-110
92. Yamashita S, Maruyama T, Hirano K, Sakai N, Nakajima N, Matsuzawa Y: Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis, 2000; 152: 271-285
93. Yamashita S, Matsuzawa Y: Where are we with probucol: a new life for an old drug? Atherosclerosis, 2009; 207: 16-23
94. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S: Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol, 1988; 62: 66B-72B
95. Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y: High-density lipoproteins from probu-col-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest, 1997; 27: 285-292
96. Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, Koseki M, Masuda D, Maruyama T, Shimomura I, Ueda Y, Yamashita S: Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol, 2005; 25: 2422-2427
97. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303
98. Meyers CD, Kashyap ML: Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol, 2004; 19: 366-373
99. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation, 2001; 104: 2376-2383
100. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC: High-density lipoprotein function recent advances. J Am Coll Cardiol, 2005; 46: 1792-1798
101. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res, 2004; 95: 764-772
102. Van Lenten BJ: Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest, 1995; 96: 2758-2767
103. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflamm-atory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 2003; 108: 2751-2756
104. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW: Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol, 1999; 19: 2226-2233
105. Watson KE, Hama S, Fonarow GC, Ansell BJ, Navab M, Fogelman AM: Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, hs-CRP and paraoxonase activity. Circulation, 2004; 110: 52
106. Kaysen GA: Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr, 2007; 17: 4-8
107. Arai T, Wang N, Bezouevski M, Welch C, Tall AR: Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem, 1999; 274: 2366-2371
108. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, Kruijt JK, Kuipers F, Van Berkel TJ: Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem, 2003; 278: 23699-23705
109. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y: Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem, 1994; 116: 257-262
110. Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, Kobayashi J, Koizumi J, Nakajima K, Nakano T, Niimi M, Mabuchi H, Yamagishi M: Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta, 2009; 402: 19-24
111. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest, 2006; 116: 1435-1442
112. Okamura T, Sekikawa A, Kadowaki T, El-Saed A, Abbott RD, Curb JD, Edmundowicz D, Nakamura Y, Murata K, Kashiwagi A, Sutton-Tyrrell K, Evans RW, Zmuda JM, Maegawa H, Hozawa A, Mitsunami K, Nishio Y, Miljkovic-Gacic I, Horie M, Miyamatsu N, Murakami Y, Kuller LH, Ueshima H: Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men. Am J Cardiol, 2009; 104: 818-822
113. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T: Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res, 2004; 45: 174-185
114. Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH: Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrin Metab, 2008; 93: 430-437
115. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, Maisch B, Steinmetz A: Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis, 1999; 144: 177-184
116. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ: Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol, 2007; 34: 1459-1464
117. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Internal Med, 2002; 251: 338-347
118. Blatter MC, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipopro tein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem, 1993; 211: 871-879
119. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991; 286: 152-154
120. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993; 104: 129-135
121. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1994; 394: 284-287
122. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits highdensity lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest, 1998; 101: 1581-1590
123. Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F, Hashimoto K: Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism, 2005; 54: 142-150
124. Arii K, Suehiro T, Ota K, Ikeda Y, Kumon Y, Osaki F, Inoue M, Inada S, Ogami N, Takata H, Hashimoto K, Terada Y: Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis, 2009; 202: 439-445
125. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G: The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol, 2008; 66: 366-374
126. Kassai A, Illyés L, Mirdamadi HZ, Seres I, Kalmár T, Audikovszky M, Paragh G: The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem, 2007; 40: 1-5
127. Deakin S, Leviev I, Guernier S, James RW: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory elementbinding protein-2. Arterioscler Thromb Vasc Biol, 2003; 23: 2083-2089
128. Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, Jukema JW: Effect of rosuvastatin versus atorvastatin treatment on paraox-onase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin, 2007; 23: 2235-2240
129. Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P: Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin, 2004; 20: 1321-1327
130. Okajima F: Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta, 2002; 1582: 132-137
131. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H: Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol, 2007; 150: 470-479
132. Nakatani N: Efficacy of statins. Prog Med, 2004; 24: 9-14
133. Teramoto T, Goto Y, Kurokawa K, Nakamura H, Yoshida S, Yasugi T, Itakura H, Takaku F, Yamada N, Hata Y, Nakaya N, Kazuya F, Mabuchi H, Kita T, Tarui S, Matsuzawa Y, Yamamoto A, Tsushima M, Kajiyama G, Arakawa K, Ishiok, T: Clinical efficacy of Fluvastatin, a new synthetic HMG-CoA reductase inhibitor, in the longterm treatment of hyperlipidemia -results of a multicenter long-term study. Rinsho Iyaku, 1995; 11: 235-265
134. Kurihara Y, Douzono T, Kawakita K, Fujita S, Nachi S, Nagasaka Y: A Largescale, Prospective Postmarketing Surveillance of Pitavastatin (LIVALO® Tablet) -Drug Use Investigation-. Jpn Pharmacol Ther, 2007; 35: 9-40
135. Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N: Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb, 2008; 15: 345-350
136. Shitara Y, Sugiyama Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther, 2006 112: 71-105
137. Nezasa K, Takao A, Kimura K, Takaichi M, Inazawa K, Koike M: Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica, 2002; 32: 715-727
138. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, Göller G, Schwarz T, Siefert HM: Cerivastatin, a new inhibitor of HMG-CoA reductase -pharmacokinetics in rats and dogs-. Jpn Pharmacol Ther, 1996; 24: S1217-S1237
139. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, Tanaka M: Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet, 1992; 17: 103-113
140. Nemoto H, Ebine H, Ohzone Y, Jin Y, Esumi Y, Kaneko K, Watanabe M, Oishi S: Pharmacokinetic studies on CI-981 (1) -absorption, distribution and excretion in rats following single oral or intravenous administrations -.Jpn Pharmacol Ther, 1998; 26: 1147-1164
141. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y: Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase(1): absorption, distribution, metabolism and excretion in rats. Xenobio Metabol And Dispos, 1998; 13: 484-498
142. Uchiyama N, Saito Y, Kagami Y, Hara K, Saito K, Sawasaki Y, Ohtawa M: Metabolic fate of simvastatin, an inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion of [14C] simvastatin after single administration in male rats. Xenobio Metabol And Dispos, 1990; 5: 133-149
143. Matsuda N, Akasaka I, Ohtawa M: Metabolic fate of fluvastatin, an inhibitor of HMG-CoA reductase (1): absorption, distribution and excretion of [14C] fluvastatin after single administration in rats. Xenobio Metabol And Dispos, 1995; 10: 513-528
144. Parini P, Gustafsson U, Davis MA, Larsson L, Einarsson C, Wilson M, Rudling M, Tomoda H, Omura S, Sahlin S, Angelin B, Rudel LL, Eriksson M: Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Arterioscler Thromb Vasc Biol, 2008; 28: 1200-1206
145. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293-302
146. Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML: Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism, 2008; 57: 973-979
147. Vergès B, Florentin E, Baillot-Rudoni S, Petit JM, Brindisi MC, Pais de Barros JP, Lagrost L, Gambert P, Duvillard L: Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J Lipid Res, 2009; 50: 1209-1215
148. Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, Remenyik E: Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol, 2004; 60: 685-691
149. Contacos C, Barter PJ, Vrga L, Sullivan DR: Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis, 1998; 141: 87-98
150. Beltowski J, Wójcicka G, Jamroz A: Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol, 2004; 43: 121-127
151. Gouédard C, Koum-Besson N, Barouki R, Morel Y: Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol, 2003; 63: 945-956
152. Dullaart RP, de Vries R, Voorbij HA, Sluiter WJ, van Tol A: Serum paraoxonase-I activity is unaffected by shortterm administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur J Clin Invest, 2009; 39: 200-203
153. Tomás M, Sentí M, García-Faria F, Vila J, Torrents A, Covas M, Marrugat J: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol, 2000; 20: 2113-2119
154. Mauger JF, Couture P, Paradis ME, Lamarche B: Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis, 2005; 178: 157-163
155. Bonn V, Cheung RC, Chen B, Taghibiglou C, Van Iderstine SC, Adeli K: Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis, 2002; 163: 59-68
156. Tomlinson B, Mak TW, Tsui JY, Woo J, Shek CC, Critchley JA, Masarei JR: Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients wit hypercholesterolemia. Am J Cardiol, 1995; 76: 36A-139A